The global Preimplantation Genetic Testing (PGT) (PGS/PGD) market size was estimated at USD 74.72 million in 2018 and is expected to expand at a CAGR of 6.2% over the forecast period. Recent technological advancements have profoundly changed thecurrent practice of prenatal screening and early detection of chromosomal abnormalities in an embryo. Broadening of non-invasive cell-free fetal DNA-based detection processes as well as carrier screening panels into prenatal care has resulted in successful in vitro fertilization (IVF) processing. This has motivated early detection of congenital diseases in initial stages of the IVF workflow that successively minimizes the risk of inherited chromosomal abnormalities in fetus, driving the preimplantation genetic testing (PGT) market.
Rising incidence single gene,mitochondrial, and other gene-related disorders, are attributed to increasing demand for preimplantation diagnosis and screening processes. As per the estimates made by the Florida Department of Health, about one in every 28 babies is diagnosed with a birth defect in Florida each year. Preimplantation Genetic Diagnosis (PGD) is implemented prior to IVF workflow for successful pregnancy. PGD is applicable in IVF cycles of women who faced several miscarriages or had last pregnancy with a chromosome abnormality. PGD can benefit the couples who are at risk of hereditary disorders, positively influencing the market.
The concept of aneuploidy screening during PGD has enhanced the IVF procedures. The introduction of aneuploidy testing in IVF centers identifies abnormal embryos; resulting in successful pregnancy rates. In August 2018, a study of Fertility and Sterility analyzed the successful IVF pregnancy outcomes by using Natera’s Spectrum PGT for aneuploidy (PGT-A).
Moreover, subsequent innovations in genetic diagnosis such as an introducing PGT monogenic disease diagnosis (PGT-M), stimulates the industrial growth. PGT-M focus on identification of Mendelian genetic disorder in embryo for addressing challenges of prenatal diagnosis as it precludes the chances of elective termination of pregnancy.
Number of supportive initiatives adopted by the government authorities to promote reproductive health, also drive the market. For instance, in June 2017, Switzerland government approved the pre-implantation genetic diagnosis of an in-vitro embryo. Such initiatives focus on detecting and minimizing genetic anomalies affecting embryos before implantation.
Ethical acceptability and legal regulations by public entities impede the adoption rate of PGT services thereby hampering the growth. However, awareness regarding health of fetus among couples and expanding applications of PGD and Preimplantation Genetic Screening (PGS) collectively create opportunities for market progression.
PGD segment held the largest market share in 2018 owing to growing awareness among healthcare professionals as well as customers about genetic testing of a specific gene mutation. Rising incidence of single gene diseases and translocation cases accompanied by effective delivery of NGS technology for genetic testing by market entities spurs the growth.
On the other hand, PGS services enable screening of embryos for chromosomal abnormalities. These services are suggested for couples with advanced reproductive age, multiple IVF cycles, and recurrent pregnancy loss. PGS services segment is anticipated to showcase lucrative growth during the forecast period, due to continuous rising demand and efficacious evolution of IVF procedures. Moreover, a large number of IVF processes are conducted in high capacity laboratories due to the presence of better facilities, which in turn enhance the quality of PGS services, thereby driving the growth.
Role of preimplantation genetic testing in embryo HLA typing for stem cell therapy generated maximum revenue in 2018. This is because hematopoietic stem cell transplantation from interconnected matched donors result in higher survival rate as compared to unrelated donors. However, application of PGT in inherited genetic diseases examination is expected to witness the fastest CAGR in near future. The rising number of inherited genetic diseases such as cystic fibrosis, hemoglobin disorders, and others, in offspring and inheritance of these diseases by future generation augments the demand.
Implementation of PGT for detecting chromosomal abnormalities, led the market in 2018 in terms of revenue generation. This is subjected to the constant development in the detecting techniques for aneuploidies that is highly prevalent in advanced maternal age.
Human Leukocyte Antigen (HLA) typing segment is estimated to witness significant CAGR during the forecast period. High success rate of hematopoietic reconstitution in babies due to stem cells transplantation attained from the HLA-matched offspring is anticipated to fuel the segment growth.
Europe preimplantation genetic testing market led in terms of revenue generated in 2018, attributed to large number of late pregnancies cases resulting in the higher adoption of IVF procedures. In addition, liberal regulations associated with aneuploidy screening also augments European PGT market.
Asia Pacific is anticipated to register the fastest CAGR during the forecast period. Emerging nations such as China and India are involved in a number of advancements related to reproductive health accompanied by the launch of several supportive governmental legislations. Presence of regulatory bodies, such as the Japanese Society of Obstetrics and Gynecology (JSOG), which approves and monitor the challenges associated with reproductive health in Japan; is anticipated to bode well for regional growth. Furthermore, increased utilization of IVF procedures translates into high adoption of PGT workflow and consequently accelerates the Asia Pacific PGT market.
Some of the key players are Illumina Inc.; Thermo Fisher Scientific, Inc.; Natera, Inc.; Bioarray S.L.; Good Start Genetics, Inc.; Laboratory Corporation of America Holdings; California Pacific Medical Center; Quest Diagnostics Incorporated; Reproductive Health Science Ltd.; CooperSurgical, Inc.; Genea Limited; IGENOMIX; Reproductive Genetic Innovations, LLC; F. Hoffmann-La Roche AG; and CombiMatrix.
Continuous developments incorporated by key participants in genetic diagnosis for successful implementation of PGT as well as screening, expands their market share significantly. Key players adopt several strategic initiatives such as geographical expansions, collaborative developments, and new product developments.
Base year for estimation
Actual estimates/Historic data
2014 - 2017
2019 - 2024
Revenue in USD Million & CAGR from 2019 to 2024
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, U.K., Germany, Spain,Belgium, Czech Republic, Poland, Sweden, Finland, Norway, Netherlands, Italy, Japan, China,India, Singapore, Malaysia, Brazil, Mexico, Argentina, Chile, South Africa.
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, abd country level and provides an analysis of the latest latest trends and opportunities in each of the sub-segments from 2014 to 2024. For the purpose of this report, Grand View Research has segmented the global Preimplantation Genetic Testing (PGT) (PGS/PGD) market on the basis of PGD/PGS, type, application, and region:
PGD/PGS Outlook (Revenue, USD Million, 2014 - 2024)
Preimplantation Genetic Diagnosis (PGD)
Preimplantation Genetic Screening (PGS)
Type Outlook (Revenue, USD Million, 2014 - 2024)
Fresh Embryo (Own Eggs)
Frozen Embryo (Own Eggs)
Fresh Embryo (Donor Eggs)
Frozen Embryo (Donor Eggs)
Other PGT Types
Application Outlook (Revenue, USD Million, 2014 - 2024)
Embryo HLA Typing for Stem Cell Therapy
Late Onset Genetic Disorders
Inherited Genetic Disease
Regional Outlook (Revenue, USD Million, 2014 - 2024)
Middle East & Africa
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPA norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.